ReviewExperimental dermatology2021
Matrix metalloproteinases in keratinocyte carcinomas.
Review in Experimental dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 41 citations in OpenAlex.
- Identification of cancer-associated fibroblast biomarkers in cutaneous squamous cell carcinoma.Oncology letters · 2026Article
- 6PPDQ Promotes Cutaneous Squamous Cell Carcinoma Growth with PI3K-Akt/MMP9 Activation: Evidence from Integrated Network Toxicology and Experimental Investigation.International journal of molecular sciences · 2026Article
- Insulin Resistance and Cutaneous Squamous Cell Carcinoma: A Narrative Review of Molecular Mechanisms.Iranian journal of medical sciences · 2026Review
- Article
- Article
- Cu-Cy Nps@ZIF-8@HA-Mediated Photodynamic Therapy for Cutaneous Squamous Cell Carcinoma.International journal of nanomedicine · 2026Article
- High-Throughput 3D Bioprinted Organoids of Skin Cancer Utilized for Diagnosis and Personalized Therapy.Current oncology (Toronto, Ont.) · 2025Review
- Multi-omics analysis reveals the crosstalk of epigenetic regulatory networks in cutaneous squamous cell carcinoma progression.Journal of translational medicine · 2025Article
- Role ofBiomedical reports · 2025Review
- MMP-2-Potential Predictor of Epithelial-Mesenchymal Transition in Squamous Cell Carcinogenesis.Life (Basel, Switzerland) · 2025Article
- PD-L1 Inhibitor Cosibelimab for Cutaneous Squamous Cell Carcinoma: Comprehensive Evaluation of Efficacy, Mechanism, and Clinical Trial Insights.Biomedicines · 2025Review
- METTL1 coordinates cutaneous squamous cell carcinoma progression via the m7G modification of the ATF4 mRNA.Cell death discovery · 2025Article
- Effective Treatment of Basal Cell Carcinoma with a Topical Enzymatic Mixture Enriched in Bromelain: Summary of Proof-Of Concept Clinical Studies on the First 22 Tumors.Journal of clinical medicine · 2024Article
- Biomarkers in Cutaneous Keratinocyte Carcinomas.Dermatology and therapy · 2024Review
- Clustering of RNA co-expression network identifies novel long non-coding RNA biomarkers in squamous cell carcinoma.Scientific reports · 2024Article
- Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosa.EMBO molecular medicine · 2024Article
- Nutlin-3 Loaded Ethosomes and Transethosomes to Prevent UV-Associated Skin Damage.Life (Basel, Switzerland) · 2024Article
- Role of reactive oxygen species in ultraviolet-induced photodamage of the skin.Cell division · 2024Review
- Case report: Basal cell carcinoma arising within the nevus sebaceous: report of 4 cases and literature review.Frontiers in oncology · 2024Article
- Inhibition of TGF-β signaling, invasion, and growth of cutaneous squamous cell carcinoma by PLX8394.Oncogene · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of cutaneous keratinocyte-derived cancers is increasing globally. Basal cell carcinoma (BCC) is the most common malignancy worldwide, and cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer. BCC can be classified into subtypes based on the histology, and these subtypes are classified further into low- and high-risk tumors. There is an increasing need to identify new therapeutic strategies for the treatment of unresectable and metastatic cSCC, and for aggressive BCC variants such as infiltrating, basosquamous or morpheaform BCCs. The most important risk factor for BCC and cSCC is solar UV radiation, which causes genetic and epigenetic alterations in keratinocytes. Similar gene mutations are noted already in sun-exposed normal skin emphasizing the role of the alterations in the tumor microenvironment in the progression of cSCC. Early events in cSCC progression are alterations in the composition of basement membrane and dermal extracellular matrix induced by influx of microbes, inflammatory cells and activated stromal fibroblasts. Activated fibroblasts promote inflammation and produce growth factors and proteolytic enzymes, including matrix metalloproteinases (MMPs). Transforming growth factor-β produced by tumor cells and fibroblasts induces the expression of MMPs by cSCC cells and promotes their invasion. Fibroblast-derived keratinocyte growth factor suppresses the malignant phenotype of cSCC cells by inhibiting the expression of several MMPs. These findings emphasize the importance of interplay of tumor and stromal cells in the progression of cSCC and BCC and suggest tumor microenvironment as a therapeutic target in cSCC and aggressive subtypes of BCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.